Loren Data's SAM Daily™

FBO DAILY ISSUE OF AUGUST 01, 2008 FBO #2440
SOLICITATION NOTICE

66 -- Laboratory Testing Services

Notice Date

7/30/2008
 

Notice Type

Presolicitation
 

NAICS

334516 — Analytical Laboratory Instrument Manufacturing
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
 

ZIP Code

20892-7902
 

Solicitation Number

NHLBI-PB-AR-2008-208-RCO
 

Archive Date

8/28/2008
 

Point of Contact

Rosie C Owens,, Phone: (301) 435-7920, Kathleen Marsden,, Phone: 301.435.0364
 

E-Mail Address

rowens@mail.nih.gov, marsdenk@nhlbi.nih.gov
 

Small Business Set-Aside

Total Small Business
 

Description

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation number is NHLBI-PB-(AR)-2008-208-RCO and is issued as a Request for Quotation (RFQ). The solicitation will include all applicable provisions and clauses in effect through Federal Acquisition Circular 05-26 (as of 06/12/2008). The North American Industry Classification (NAICS) Code is 334516, and the business size standard is 500. This acquisition is being conducted using Simplified Acquisition Procedures in accordance with FAR Part 13. However, this solicitation is set aside for small businesses. It is the intent of the National Heart, Lung, and Blood Institute’s (NHLBI) Consolidated Operations Acquisition Centers (COAC) on behalf of National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to procure the services from BioScan, Inc. 4590 MacArthur Blvd. N.W. Washington, D.C. 20007 for the following product and service: a)One (1), 330SL Automatic TDCR Liquid Scintillation Counter, no. HI-425-201, b) on-site installation and training w/ 300SL TDCR, no. HI-INST300 Summary: The above laboratory equipment is essential to NIAMS’s continued research efforts: Background: Laboratory of Muscle Stem Cells and Gene Regulation The p300 and PCAF acetyltransferases are nodal coactivators of the muscle specific transcription factor MyoD. MyoD is acetylated by PCAF resulting in an increased transcriptional activity. Acetylation and deacetylation are in a dynamic equilibrium and we have now begun to explore the role of nuclear deacetylases in controlling muscle differentiation. Data generated in our laboratory indicate that the deacetylase HDAC-1 counteracts the ability of MyoD to convert naïve fibroblasts to muscle cells and impedes differentiation of cultured mouse myoblasts. The molecular basis of this phenomenon correlates with the ability of HDAC-1 to physically interact with and deacetylate both MyoD and histones surrounding chromatin MyoD-binding sites in undifferentiated myoblasts. Upon induction of cellular differentiation, the tumor suppressor protein pRb is dephosphorylated, engages HDAC-1 and blocks transcription of genes controlled by the transcription factor E2F and required for G1 progression. During this process, HDAC-1 is physically displaced from MyoD to pRB allowing acetylation of MyoD by the acetyltrasferases PCAF thereby promoting transcriptional activation and cellular differentiation. We are now interested in defining the cellular signals regulating the acetylase and deacetylase activities. Expression profiling of skeletal muscle cells exposed to small molecule inhibitors We have evaluated the effects of global acetylation during muscle differentiation by employing the specific deacetylase inhibitors (DI) sodium butyrate, trichostatin A (TSA), and valproic acid (VPA). Our results indicate that mouse, human myoblasts and mouse developing embryos exposed to a temporally defined regimen of DI display a muscle hypertrophic response as judged by an increase d expression of muscle-specific markers, multinucleation and increased fiber diameter. To identify the molecules mediating the DI effects, we have initiated an expression profiling of cells treated with TSA. We plan to profile muscle gene expression in response to several small molecule inhibitors. Biochemical Characterization of Proteins Associated with MyoDTo isolate proteins interacting with MyoD we have developed a bicistronic retroviral system for cellular delivery of MyoD. Large quantities of cells are grown and protein purification performed by affinity chromatography using FLAG-immobilized agarose beads. The MyoD-associated factors (MAFs) are identified by mass spectrometry. We have also generated cells expressing a version of MyoD that cannot be acetylated and are interested in determining and compare the pattern of the MAFs isolated using both MyoD 'wild-type' and non-acetylatable MyoD. Selected Publications Fulco M, Cen Y, Zhao P, Hoffman EP, McBurney MW, Sauve AA, Sartorelli V. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell. 2008 May;14(5):661-73. Di Padova M, Caretti G, Zhao P, Hoffman EP, Sartorelli V. Myod acetylation influences temporal patterns of skeletal muscle gene expression. J Biol Chem. 2007 Oct 27; [Epub ahead of print] Caretti G., Schiltz R.L., Dilworth F.J., Di Padova M., Zhao P., Ogryzlo V., Fuller-Pace F., Hoffman E.P, Tapscott S.J., and Sartorelli V. The RNA helicases p68/p72 and the noncoding RNA SRA are coregulators of MyoD and skeletal muscle differentiation. Dev Cell. 2006; 11(4):547-60. Minetti G.C., Colussi C., Adami R., Serra C., Mozzetta C., Parente V., Fortuni S., Straino S., Sampaolesi M., Di Padova M., Illi B., Capogrossi M.C., Sartorelli V., Bottinelli R., Gaetano C., Puri P.L. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med. 2006; 12(10):1147-50. Iezzi S, Di Padova M, Serra C, Caretti G, Simone C, Maklan E, Minetti G, Zhao P, Hoffman EP, Puri PL, Sartorelli V. Deacetylase Inhibitors Increase Muscle Cell Size by Promoting Myoblast Recruitment and Fusion through Induction of Follistatin. Dev Cell. 2004; 6(5): 673-84. The sole source determination is based upon the fact that the Laboratory of Muscle Stem Cells and Gene Regulation has limited space requirement, only this vendor’s product will fit into the space available for this equipment. In the lab, the required specification for the liquid scintillation counter must have a small footprint which shall be placed in a lab bench that measures 31x28 inches. Through market research conducted by the government; (Far 10) only three companies manufacture this type of equipment. Only BioScan Inc.’s scintillation provided the required dimensions at 26.7, w 20, and 25.2 inches that would fit and meet the governments need. Delivery date: Thirty days after receipt of purchase order The offeror must include a completed copy of the following provisions: 1) FAR Clause 52.212-1 Instructions to Offerors Commercial; 2) FAR Clause 52.212-2, Evaluation Commercial Items. As stated in FAR Clause 52.212-2 (a), The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: Technical Evaluation and Price. 3) FAR Clause 52.212-3, Offeror Representations and Certifications Commercial Items; 4) FAR Clause 52.212-4, Contract Terms and Conditions Required To Implement Statues or Executive Orders Commercial Items, Contract Terms and Conditions Commercial Items; and 5) FAR Clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items Deviation for Simplified Acquisitions. This action is under the authority of 41 U.S.C. 253(c) (1), as set forth in FAR 6.302-1 and HHSAR 306-302-1. Only one responsible source and no other supplies or services will satisfy agency requirement. This notice of intent is not a request for competitive quotations however; all responses received within 15 days from the date of publication of this synopsis will be considered by the Government. Interested parties may identify their interest and capability to respond to the requirement or submit proposals. However, the determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. The offeror must include in their quotation, the unit price, the list price, shipping and handling cost. Note: In order to receive an award from the NHLBI contractors must have a valid registration in the Central Contractor Registration (CCR) www.ccr.gov and registered in Dun and Bradstreet (DUNS), the Taxpayer Identification and the certification of business size www.bpn.gov. The clauses are available in full text at http://www.arnet.gov/far. Quotations will be due fifteen (15) calendar days from the publication date of this synopsis or by August 13, 2008, 5pm, Eastern Standard Time. Responses will only be accepted if dated and signed by an authorized company representative. Interested vendors capable of furnishing the government with the item specified in this synopsis should submit their quotation to the below address. Inquires to this notice, referencing number NHLBI-PB-(AR)-2008-208-RCO, submitted in writing to the National Heart, Lung and Blood Institute, Office of Acquisition, Procurement Branch, 6701 Rockledge Drive, Suite 6128, Bethesda, Maryland 20892-7902. Attention: Ms. Rosie C. Owens, Contract Specialist. If submitted electronically: Email: Rosie C. Owens, Contract Specialist rowens@nhlbi.nih.gov or Ms. Kathleen Marsden, Contracting Officer marsdenk@nhlbi.nih.gov. Faxed copies will not be accepted.
 

Web Link

FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=009f087d92cf461fe534e3fdcf9cbff6&tab=core&_cview=1)
 

Place of Performance

Address: Bethesda, Maryland, 20892-0001, United States

Zip Code: 20892-0001
 

Record

SN01626791-W 20080801/080730221849-009f087d92cf461fe534e3fdcf9cbff6 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |